AstraZeneca Takes Five: DTC Study Finds Five Risks Per Ad Is Optimal For Recall

An AstraZeneca study on consumer communication through direct-to-consumer television advertisements identifies five risks as the optimal number to include in order to ensure consumer recall of safety information

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet